I/We Claim:

1. A compound of Formula (I)



(I)

their stereoisomers and pharmaceutically acceptable salts thereof,

wherein, X_1 is selected from $-CH_2O-$ or $-OCH_2-$;

R_4 is hydrogen or C_{1-6} alkyl;

X is selected from CR_3 or N;

R_1, R_2, R_3, R_6 and R_7 are independently selected from hydrogen, halo, C_{1-6} alkyl, (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, OR^a and $C(O)OR^a$, wherein, the C_{1-6} alkyl, and (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, are independently optionally substituted with 1, 2 or 3 R^b substituents;

R^a is selected from hydrogen, C_{1-6} alkyl, C_{1-4} haloalkyl, C_{6-10} aryl-C_{1-4} alkyl-, C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-10 membered heteroaryl)-C_{1-4} alkyl-, or (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, wherein, the C_{1-6} alkyl, C_{6-10} aryl-C_{1-4} alkyl-, C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-10 membered heteroaryl)-C_{1-4} alkyl- and (4-10 membered heterocycloalkyl)-C_{1-4} alkyl- are independently optionally substituted with 1, 2 or 3 R^d substituents;

R^b is selected from hydroxy, amino, C_{1-4} alkyl, 4-10 membered heterocycloalkyl, OR^c, $C(O)NR^cR^c$, $C(O)OR^c$, NHR^c, NR^cR^c, or $NR^cC(O)R^c$; wherein, the C_{1-4} alkyl, and 4-10 membered heterocycloalkyl, are optionally substituted with 1, 2 or 3 R^d substituents;

R^c is selected from hydrogen, C_{1-6} alkyl, or C_{3-10} cycloalkyl, wherein, the C_{1-6} alkyl, and C_{3-10} cycloalkyl, are optionally substituted with 1, 2 or 3 R^f substituent;

R^d is selected from cyano, C_{1-6} alkyl, halo, C_{6-10} aryl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, $C(O)NR^eR^e$, or $C(O)OR^e$, wherein, C_{6-10} aryl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl, and 4-10 membered heterocycloalkyl, are optionally substituted with 1, 2, or 3 R^f substituents;

R^f is selected from C_{1-4} alkyl, halogen, CN, OR^g, $C(O)NR^gR^g$, $C(O)OR^g$, or $NR^gC(O)R^g$;

R^g is selected from hydrogen or C_{1-6} alkyl;

R^e is selected from hydrogen, or C_{1-4} alkyl;

m is 1 or 2;

Ring A is substituted or unsubstituted C_{6-10} aryl, substituted with C_{1-4} alkyl, cyano or C_{1-4} haloalkyl;

Ring B is selected from C_{6-10} aryl, C_{3-6} cycloalkyl, 5-10 membered monocyclic saturated or unsaturated heterocyclic ring with 1-3 heteroatoms selected from N, S or O.

2. A compound of Formula (II)



Formula (II)

their stereoisomers and pharmaceutically acceptable salts thereof,

wherein, X_1 is selected from $-CH_2O-$ or $-OCH_2-$;

R_4 is hydrogen or C_{1-6} alkyl;

R_5 is selected from C_{1-4} alkyl, cyano, or C_{1-4} haloalkyl;

R_1, R_2, R_3, R_6 and R_7 are independently selected from hydrogen, halo, C_{1-6} alkyl, (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, OR^a, and $C(O)OR^a$, wherein, the C_{1-6} alkyl, and (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, are independently optionally substituted with 1, 2 or 3 R^b substituents;

R^a is selected from hydrogen, C_{1-6} alkyl, C_{1-4} haloalkyl, C_{6-10} aryl-C_{1-4} alkyl-, C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-10 membered heteroaryl)-C_{1-4} alkyl-, or (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, wherein, the C_{1-6} alkyl, C_{6-10} aryl-C_{1-4} alkyl-, C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-10 membered heteroaryl)-C_{1-4} alkyl- and (4-10 membered heterocycloalkyl)-C_{1-4} alkyl- are independently optionally substituted with 1, 2 or 3 R^d substituents;

R^b is selected from hydroxy, amino, C_{1-4} alkyl, 4-10 membered heterocycloalkyl, OR^c, $C(O)NR^cR^c$, $C(O)OR^c$, NHR^c, NR^cR^c, or $NR^cC(O)R^c$; wherein, the C_{1-4} alkyl, and 4-10 membered heterocycloalkyl, are optionally substituted with 1, 2 or 3 R^d substituents;

R^d is selected from cyano, C_{1-6} alkyl, halo, C_{6-10} aryl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, $C(O)NR^eR^e$, or $C(O)OR^e$, wherein, the C_{6-10} aryl, 5-10

membered heteroaryl, C_{3-10} cycloalkyl, and 4-10 membered heterocycloalkyl, are optionally substituted with 1, 2, or 3 R^f substituents;

R^c is selected from hydrogen, C_{1-6} alkyl, or C_{3-10} cycloalkyl, wherein, the C_{1-6} alkyl, and C_{3-10} cycloalkyl, are optionally substituted with 1, 2 or 3 R^f substituent;

R^f is selected from C_{1-4} alkyl, halogen, CN, OR^g, $C(O)NR^gR^g$, $C(O)OR^g$, or $NR^gC(O)R^g$;

R^g is selected from hydrogen, or C_{1-6} alkyl;

R^e is selected from hydrogen, or C_{1-4} alkyl;

Ring B is selected from C_{6-10} aryl, C_{3-6} cycloalkyl, 5-10 membered monocyclic saturated or unsaturated heterocyclic ring with 1-3 heteroatoms selected from N, S or O.

3. A compound of Formula (III)



Formula (III)

their stereoisomers and pharmaceutically acceptable salts thereof,

wherein, X_1 is selected from $-CH_2O-$ or $-OCH_2-$;

R_4 is hydrogen or C_{1-6} alkyl;

R_5 is selected from C_{1-4} alkyl, cyano, or C_{1-4} haloalkyl;

R_1, R_2, R_3, R_6 and R_7 are independently selected from hydrogen, halo, C_{1-6} alkyl, (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, OR^a, and $C(O)OR^a$, wherein, the C_{1-6} alkyl, and (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, are independently optionally substituted with 1, 2 or 3 R^b substituents;

R^a is selected from hydrogen, C_{1-6} alkyl, C_{1-4} haloalkyl, C_{6-10} aryl-C_{1-4} alkyl-, C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-10 membered heteroaryl)-C_{1-4} alkyl-, or (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, wherein, the C_{1-6} alkyl, C_{6-10} aryl-C_{1-4} alkyl-, C_{3-10} cycloalkyl-C_{1-4}alkyl-, (5-10 membered heteroaryl)-C_{1-4} alkyl- and (4-10 membered heterocycloalkyl)-C_{1-4} alkyl- are independently optionally substituted with 1, 2 or 3 R^d substituents;

R^b is selected from hydroxy, amino, C_{1-4} alkyl, 4-10 membered heterocycloalkyl, OR^c, $C(O)NR^cR^c$, $C(O)OR^c$, NHR^c, NR^cR^c, or $NR^cC(O)R^c$; wherein, the C_{1-4} alkyl, and 4-10 membered heterocycloalkyl, are optionally substituted with 1, 2, or 3 R^d substituents;

R^d is selected from cyano, C_{1-6} alkyl, halo, C_{6-10} aryl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, $C(O)NR^eR^e$, or $C(O)OR^e$, wherein, the C_{6-10} aryl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl, and 4-10 membered heterocycloalkyl, are optionally substituted with 1, 2, or 3 R^f substituents;

R^c is selected from hydrogen, C_{1-6} alkyl, or C_{3-10} cycloalkyl, wherein, the C_{1-6} alkyl, and C_{3-10} cycloalkyl, are optionally substituted with 1, 2 or 3 R^f substituent;

R^f is selected from C_{1-4} alkyl, halogen, CN, OR^g, $C(O)NR^gR^g$, $C(O)OR^g$, or $NR^gC(O)R^g$;

R^g is selected from hydrogen or C_{1-6} alkyl;

R^e is selected from hydrogen or C_{1-4} alkyl.

4. A compound of Formula (IV)



Formula (IV)

their stereoisomers and pharmaceutically acceptable salts thereof,

wherein, R_5 is selected from C_{1-4} alkyl, cyano, or C_{1-4} haloalkyl;

R_1, R_2, R_3, R_6 and R_7 are independently selected from hydrogen, halo, C_{1-6} alkyl, (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, OR^a, and $C(O)OR^a$, wherein, the C_{1-6} alkyl, and (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, are independently optionally substituted with 1, 2 or 3 R^b substituents;

R^a is selected from hydrogen, C_{1-6} alkyl, C_{1-4} haloalkyl, C_{6-10} aryl-C_{1-4} alkyl-, C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-10 membered heteroaryl)-C_{1-4} alkyl-, or (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, wherein, the C_{1-6} alkyl, C_{6-10} aryl-C_{1-4} alkyl-, C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-10 membered heteroaryl)-C_{1-4} alkyl- and (4-10 membered heterocycloalkyl)-C_{1-4} alkyl- are independently optionally substituted with 1, 2 or 3 R^d substituents;

R^b is selected from hydroxy, amino, C_{1-4} alkyl, 4-10 membered heterocycloalkyl, OR^c, $C(O)NR^cR^c$, $C(O)OR^c$, NHR^c, NR^cR^c, or $NR^cC(O)R^c$; wherein, the C_{1-4} alkyl, and 4-10 membered heterocycloalkyl, are optionally substituted with 1, 2 or 3 R^d substituents;

R^d is selected from cyano, C_{1-6} alkyl, halo, C_{6-10} aryl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, $C(O)NR^eR^e$, or $C(O)OR^e$, wherein, the C_{6-10} aryl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl, and 4-10 membered heterocycloalkyl, are optionally substituted with 1, 2 or 3 R^f substituents;

R^c is selected from hydrogen, C_{1-6} alkyl, or C_{3-10} cycloalkyl, wherein, the C_{1-6} alkyl, and C_{3-10} cycloalkyl, are optionally substituted with 1, 2 or 3 R^f substituent;

R^f is selected from C_{1-4} alkyl, halogen, CN, OR^g, $C(O)NR^gR^g$, $C(O)OR^g$, or $NR^gC(O)R^g$;

R^g is selected from hydrogen or C_{1-6} alkyl;

R^e is selected from hydrogen or C_{1-4} alkyl.

5. A compound of Formula (V)



Formula (V)

their stereoisomers and pharmaceutically acceptable salts thereof,

wherein, R_5 is selected from C_{1-4} alkyl, cyano, or C_{1-4} haloalkyl;

R_4 is hydrogen or C_{1-6} alkyl;

R_1, R_2, R_3, R_6 and R_7 are independently selected from hydrogen, halo, C_{1-6} alkyl, (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, OR^a, and $C(O)OR^a$, wherein, the C_{1-6} alkyl, and (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, are independently optionally substituted with 1, 2 or 3 R^b substituents;

R^a is selected from hydrogen, C_{1-6} alkyl, C_{1-4} haloalkyl, C_{6-10} aryl-C_{1-4} alkyl-, C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-10 membered heteroaryl)-C_{1-4} alkyl-, or (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, wherein, the C_{1-6} alkyl, C_{6-10} aryl-C_{1-4} alkyl-, C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-10 membered heteroaryl)-C_{1-4} alkyl- and (4-10 membered heterocycloalkyl)-C_{1-4} alkyl- are independently optionally substituted with 1, 2 or 3 R^d substituents;

~~233~~

R^b is selected from hydroxy, amino, C_{1-4} alkyl, 4-10 membered heterocycloalkyl, OR^c, $C(O)NR^cR^c$, $C(O)OR^c$, NHR^c, NR^cR^c, or $NR^cC(O)R^c$; wherein, the C_{1-4} alkyl, and 4-10 membered heterocycloalkyl, are optionally substituted with 1, 2 or 3 R^d substituents;

R^d is selected from cyano, C_{1-6} alkyl, halo, C_{6-10} aryl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, $C(O)NR^eR^e$, or $C(O)OR^e$, wherein, the C_{6-10} aryl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl, and 4-10 membered heterocycloalkyl, are optionally substituted with 1, 2 or 3 R^f substituents;

R^c is selected from hydrogen, C_{1-6} alkyl, or C_{3-10} cycloalkyl, wherein, the C_{1-6} alkyl, and C_{3-10} cycloalkyl, are optionally substituted with 1, 2 or 3 R^f substituent;

R^f is selected from C_{1-4} alkyl, halogen, CN, OR^g, $C(O)NR^gR^g$, $C(O)OR^g$, or $NR^gC(O)R^g$;

R^g is selected from hydrogen or C_{1-6} alkyl;

R^e is selected from hydrogen or C_{1-4} alkyl.

6. A compound or its stereoisomers and pharmaceutically acceptable salts thereof, selected from a group consisting of:

(S)-1-((7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl) piperidine-2-carboxylic acid (1),

N-(2-(((5-methoxy-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl) methyl)amino)ethyl)acetamide (2),

(S)-1-((7-((3-(1-(3-(3,3-difluoropyrrolidin-1-yl)propyl)-1H-indol-4-yl)-2-methylbenzyl)oxy)-2,3-dihydro-1H-inden-4-yl)methyl)piperidine-2-carboxylic acid (3),

(S)-1-((6-methyl-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)piperidine-2-carboxylic acid (4),

(S)-1-((6-chloro-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)piperidine-2-carboxylic acid (5),

Methyl 7-(((2-acetamidoethyl)amino)methyl)-4-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-indene-5-carboxylate (6),

(S)-1-((7-((3'-(3-(3,3-difluoropyrrolidin-1-yl)propoxy)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)methoxy)-5-methoxy-2,3-dihydro-1H-inden-4-yl)methyl)piperidine-2-carboxylic acid (7),

(S)-1-((5-((3-cyanobenzyl)oxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)piperidine-2-carboxylic acid (8),

(S)-1-((5-((5-fluoropyridin-3-yl)methoxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)piperidine-2-carboxylic acid (9)

N-(2-(((5-((5-fluoropyridin-3-yl)methoxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)amino)ethyl)acetamide (10)

(S)-5-((5-methoxy-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)-5-azaspiro[2.4]heptane-6-carboxylic acid (11)

(S)-1-((7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-5-(2,2,2-trifluoroethoxy)-2,3-dihydro-1H-inden-4-yl)methyl)piperidine-2-carboxylic acid (12)

N-(2-(((5-((3-cyanobenzyl)oxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)amino)ethyl)-N-methylacetamide(13)

N-(2-(((5-(1-(3-cyanophenyl)ethoxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)amino)ethyl)acetamide (14)

N-(1-((5-((3-cyanobenzyl)oxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)piperidin-3-yl)acetamide (15)

N-(2-(((7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)amino)ethyl)acetamide (16)

6-((7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)-2-oxa-6-azaspiro[3.3]heptane (17)

2-(hydroxymethyl)-2-(((7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)amino)propane-1,3-diol (18)

1-(((7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)amino)cyclopropane-1-carboxylic acid (19)

((7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)glycine (20)

3-(((7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)amino)propanoic acid (21)

N-methyl-N-((7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)glycine (22)

3-(((7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)amino)butanoic acid (23)

((7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)alanine (24)

(2S,4R)-4-hydroxy-1-((5-methoxy-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)pyrrolidine-2-carboxylic acid (25)

(S)-1-((5-methoxy-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)piperidine-2-carboxylic acid (26)

1-((4-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-5,6,7,8-tetrahydronaphthalen-1-yl)methyl)piperidine-2-carboxylic acid (27)

N-(2-(((6-methyl-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)amino)ethyl)acetamide (28)

(2S,4R)-4-hydroxy-1-((6-methyl-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)pyrrolidine-2-carboxylic acid (29)

N-(2-(((6-chloro-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)amino)ethyl)acetamide (30)

(2S,4R)-1-((6-chloro-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)-4-hydroxypyrrolidine-2-carboxylic acid (31)

N-(2-(((7-((3'-(3-(3,3-difluoropyrrolidin-1-yl)propoxy)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)methoxy)-5-methoxy-2,3-dihydro-1H-inden-4-yl)methyl)amino)ethyl)acetamide (32)

(2S,4R)-1-((7-((3'-(3-(3,3-difluoropyrrolidin-1-yl)propoxy)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)methoxy)-5-methoxy-2,3-dihydro-1H-inden-4-yl)methyl)-4-hydroxypyrrolidine-2-carboxylic acid (33)

N-(2-(((5-((3-cyanobenzyl)oxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)amino)ethyl)acetamide (34)

(2S,4R)-1-((5-((3-cyanobenzyl)oxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)-4-hydroxypyrrolidine-2-carboxylic acid (35)

(S)-1-((5-((3-cyanobenzyl)oxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)piperidine-2-carboxylic acid (36)

(S)-1-((5-((3-cyanobenzyl)oxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)piperidine-2-carboxamide (37)

3-(((4-(((1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)amino)methyl)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-5-yl)oxy)methyl)benzonitrile (38)

3-(((4-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-5-yl)oxy)methyl)benzonitrile (39)

~~236~~

3-(((4-((3-hydroxypiperidin-1-yl)methyl)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-5-yl)oxy)methyl)benzonitrile (40)

((5-((3-cyanobenzyl)oxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)glycine (41)

(S)-5-((5-((3-cyanobenzyl)oxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)-5-azaspiro[2.4]heptane-6-carboxylic acid (42)

rac-(1R,6S)-2-((5-((3-cyanobenzyl)oxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl) methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)-2-azabicyclo[4.1.0]heptane-1-carboxylic acid (cis, racemic) (43)

4-(((5-((3-cyanobenzyl)oxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl) methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)amino)butanoic acid (44)

(1R,6S)-2-((5-methoxy-7-((2-methyl-[1,1'-biphenyl]-3-yl) methoxy)-2,3-dihydro-1H-inden-4-yl) methyl)-2-azabicyclo [4.1.0]heptane-1-carboxylic acid (cis, racemic) (45)

(S)-1-((5-((5-cyanopyridin-3-yl)methoxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl) methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)piperidine-2-carboxylic acid (46)

(2S,4R)-1-((5-((5-cyanopyridin-3-yl)methoxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)-4-hydroxypyrrolidine-2-carboxylic acid (47)

N-(2-(((5-((5-cyanopyridin-3-yl)methoxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)amino)ethyl)acetamide (48)

5-(((4-(((1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)amino)methyl)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-5-yl)oxy)methyl)nicotinonitrile (49)

(S)-4-((5-((5-cyanopyridin-3-yl)methoxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)morpholine-3-carboxylic acid (50)

rac-(1R,6S)-2-((5-((5-cyanopyridin-3-yl)methoxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)-2-azabicyclo[4.1.0]heptane-1-carboxylic acid (cis, racemic) (51)

(S)-5-((5-((5-cyanopyridin-3-yl)methoxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)-5-azaspiro[2.4]heptane-6-carboxylic acid (52)

N-(2-(((5-((3-cyanobenzyl)oxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)(methyl)amino)ethyl)acetamide (53)

N-(2-(((5-((4-cyanobenzyl)oxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)amino)ethyl)acetamide (54)

(S)-1-((7-((2-cyano-[1,1'-biphenyl]-3-yl)methoxy)-5-methoxy-2,3-dihydro-1H-inden-4-yl)methyl)piperidine-2-carboxylic acid (55)

N-(2-(((7-((2-cyano-[1,1'-biphenyl]-3-yl)methoxy)-5-methoxy-2,3-dihydro-1H-inden-4-yl)methyl)amino)ethyl)acetamide (56)

(2S,4R)-1-((7-((2-cyano-[1,1'-biphenyl]-3-yl)methoxy)-5-methoxy-2,3-dihydro-1H-inden-4-yl)methyl)-4-hydroxypyrrolidine-2-carboxylic acid (57)

3-(((7-(((1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)amino)methyl)-6-methoxy-2,3-dihydro-1H-inden-4-yl)oxy)methyl)-[1,1'-biphenyl]-2-carbonitrile (58)

(S)-4-((7-((2-cyano-[1,1'-biphenyl]-3-yl)methoxy)-5-methoxy-2,3-dihydro-1H-inden-4-yl)methyl)morpholine-3-carboxylic acid (59)

((7-((2-cyano-[1,1'-biphenyl]-3-yl)methoxy)-5-methoxy-2,3-dihydro-1H-inden-4-yl)methyl)glycine (60)

(S)-5-((7-((2-cyano-[1,1'-biphenyl]-3-yl)methoxy)-5-methoxy-2,3-dihydro-1H-inden-4-yl)methyl)-5-azaspiro[2.4]heptane-6-carboxylic acid (61)

rac-(1R,6S)-2-((7-((2-cyano-[1,1'-biphenyl]-3-yl)methoxy)-5-methoxy-2,3-dihydro-1H-inden-4-yl)methyl)-2-azabicyclo[4.1.0]heptane-1-carboxylic acid (cis, racemic) (62)

2-(1-((7-((2-cyano-[1,1'-biphenyl]-3-yl)methoxy)-5-methoxy-2,3-dihydro-1H-inden-4-yl)methyl)piperidin-2-yl)acetic acid (63)

N-(2-(((7-((2-cyano-[1,1'-biphenyl]-3-yl)methoxy)-5-methoxy-2,3-dihydro-1H-inden-4-yl)methyl)(methyl)amino)ethyl)-N-methylacetamide (64)

5-((4-(((2-acetamidoethyl)amino)methyl)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-5-yl)oxy)pentanoic acid (65)

5-((4-(((2-acetamidoethyl)amino)methyl)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-5-yl)oxy)pentanamide (66)

(S)-1-((5-(4-carboxybutoxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)piperidine-2-carboxylic acid (67)

(S)-1-((5-((5-amino-5-oxopentyl)oxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)piperidine-2-carboxylic acid (68)

(S)-1-((5-((5-cyanopyridin-3-yl)methoxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl) methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)piperidine-2-carboxylic acid (69)

(2S,4R)-1-((7-((2-cyano-[1,1'-biphenyl]-3-yl)methoxy)-5-((5-cyanopyridin-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)-4-hydroxypyrrolidine-2-carboxylic acid (70)

(R)-1-((7-((2-cyano-[1,1'-biphenyl]-3-yl)methoxy)-5-((5-cyanopyridin-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)piperidine-3-carboxylic acid (71)

rac-(1R,6S)-2-((7-((2-cyano-[1,1'-biphenyl]-3-yl)methoxy)-5-((5-cyanopyridin-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)-2-azabicyclo[4.1.0]heptane-1-carboxylic acid (cis racemic) (72)

Methyl 4-(((5-((3-cyanobenzyl)oxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)amino)bicyclo[2.2.2]octane-1-carboxylate (73)

4-(((5-((3-cyanobenzyl)oxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)amino)bicyclo[2.2.2]octane-1-carboxylic acid (74)

(S)-1-((5-methoxy-7-((2-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)piperidine-2-carboxylic acid (75)

(2S,4R)-4-hydroxy-1-((5-methoxy-7-((2-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)pyrrolidine-2-carboxylic acid (76)

(2S)-1-((7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-5-((1-methylpiperidin-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)piperidine-2-carboxylic acid (77)

(S)-1-((5-(4-carboxybutoxy)-7-((2-cyano-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)piperidine-2-carboxylic acid (78)

N-(2-(((5-(4-cyanobutoxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)amino)ethyl)acetamide (79)

(S)-1-((5-(4-cyanobutoxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)piperidine-2-carboxamide (80)

(2S,4R)-1-((5-(4-cyanobutoxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)-4-hydroxypyrrolidine-2-carboxylic acid (81)

(S)-1-((5-(((1S,2R)-2-carboxycyclopropyl)methoxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)piperidine-2-carboxylic acid (82)

(1R,2S)-2-(((4-(((2-acetamidoethyl)amino)methyl)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-5-yl)oxy)methyl)cyclopropane-1-carboxylic acid (83)

(S)-1-((7-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-5-methoxy-2,3-dihydro-1H-inden-4-yl)methyl)piperidine-2-carboxylic acid (84)

(2S,4R)-1-((7-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-5-methoxy-2,3-dihydro-1H-inden-4-yl)methyl)-4-hydroxypyrrolidine-2-carboxylic acid (85)

N-(2-(((5-((3-cyanobenzyl)oxy)-7-((2,2'-dimethyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)amino)ethyl)acetamide (86)

N-(2-(((5-((3-cyanobenzyl)oxy)-7-((4'-fluoro-2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)amino)ethyl)acetamide (87)

(S)-1-((5-((3-carbamoylbenzyl)oxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)piperidine-2-carboxylic acid (88)

3-(((4-(aminomethyl)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-5-yl)oxy)methyl)benzonitrile (89)

N-((5-((3-cyanobenzyl)oxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl) methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)acetamide (90)

6-acetamido-N-((5-((3-cyanobenzyl)oxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)hexanamide (91)

3-(((4-((dimethylamino)methyl)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-5-yl)oxy)methyl)benzonitrile (92)

5-(((4-(((2-acetamidoethyl)amino)methyl)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-5-yl)oxy)methyl)nicotinic acid (93)

5-(((4-(((2-acetamidoethyl)amino)methyl)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-5-yl)oxy)methyl)nicotinamide (94)

3-(((4-(((2-acetamidoethyl)amino)methyl)-7-((2-methyl-[1,1'-biphenyl] -3-yl)methoxy)-2,3-dihydro-1H-inden-5-yl)oxy)methyl)benzamide (95)

(S)-1-((3-methoxy-1-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-6,7-dihydro-5H-cyclopenta[c]pyridin-4-yl)methyl)piperidine-2-carboxylic acid (96)

N-(2-(((3-methoxy-1-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-6,7-dihydro-5H-cyclopenta[c]pyridin-4-yl)methyl)amino)ethyl)acetamide (97)

(S)-4-((5-methoxy-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)morpholine-3-carboxylic acid (98)

5-((5-((3-cyanobenzyl)oxy)-7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydro-1H-inden-4-yl)methyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (99)

7. A process of preparation of compounds of Formula (I), as claimed in claim 1 or its stereoisomers and pharmaceutically acceptable salts thereof.

8. The process of preparation of compounds of Formula (I) as claimed in claim 7, comprising: (a) reacting compounds of Formula I (a) with substituted aliphatic, aromatic, heterocyclic and cyclic amines to obtain compounds of Formula (I)



Formula (I) (a) Formula (I)

wherein, the X_1 of Formula I (a) and Formula (I) is selected from $-CH_2O-$ or $-OCH_2-$; R_4 of Formula I (a) and Formula (I) is hydrogen or C_{1-6} alkyl; X of Formula I (a) and Formula (I) is selected from CR_3 or N; R_1, R_2, R_3, R_6 and R_7 of Formula I (a) and Formula (I) are independently selected from hydrogen, halo, C_{1-6} alkyl, (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, OR^a, and $C(O)OR^a$, wherein, the C_{1-6} alkyl, and (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, are independently optionally substituted with 1, 2 or 3 R^b substituents; R^a is selected from hydrogen, C_{1-6} alkyl, C_{1-4} haloalkyl, C_{6-10} aryl-C_{1-4} alkyl-, C_{3-10} cycloalkyl-C_{1-4} alkyl-, (5-10 membered heteroaryl)-C_{1-4} alkyl-, or (4-10 membered heterocycloalkyl)-C_{1-4} alkyl-, wherein, the C_{1-6} alkyl, C_{6-10} aryl-C_{1-4} alkyl-, C_{3-10} cycloalkyl-C_{1-4}alkyl-, (5-10 membered heteroaryl)-C_{1-4} alkyl- and (4-10 membered heterocycloalkyl)-C_{1-4} alkyl- are independently optionally substituted with 1, 2 or 3 R^d substituents; R^b is selected from hydroxy, amino, C_{1-4} alkyl, 4-10 membered heterocycloalkyl, OR^c, $C(O)NR^cR^c$, $C(O)OR^c$, NHR^c, NR^cR^c, or $NR^cC(O)R^c$; wherein, the C_{1-4} alkyl, and 4-10 membered heterocycloalkyl, are optionally substituted with 1, 2 or 3 R^d substituents; R^c is selected from hydrogen, C_{1-6} alkyl, or C_{3-10} cycloalkyl, wherein, the C_{1-6} alkyl, and C_{3-10} cycloalkyl, are optionally substituted with 1, 2 or 3 R^f substituent;

R^d is selected from cyano, C_{1-6} alkyl, halo, C_{6-10} aryl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, $C(O)NR^eR^e$, or $C(O)OR^e$, wherein, the C_{6-10} aryl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl, and 4-10 membered heterocycloalkyl, are optionally substituted with 1, 2 or 3 R^f substituents;

R^f is selected from C_{1-4} alkyl, halogen, CN, OR^g, $C(O)NR^gR^g$, $C(O)OR^g$, or $NR^gC(O)R^g$; R^g is selected from hydrogen or C_{1-6} alkyl; R^e is selected from hydrogen or C_{1-4} alkyl; m is 1 or 2; Ring A is selected from substituted or unsubstituted C_{6-10} aryl, substituted with C_{1-4} alkyl, cyano or C_{1-4} haloalkyl; Ring B is selected from C_{6-10} aryl, C_{3-6} cycloalkyl, 5-10 membered monocyclic saturated or unsaturated heterocyclic ring with 1-3 heteroatoms selected from N, S or O, with substituted amines in the presence of solvents to obtain compounds of Formula (I).

9. A pharmaceutical composition comprising a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, or a pharmaceutically acceptable salt thereof as claimed in any of the claims 1-6, together with a pharmaceutically acceptable carrier, optionally in combination with one or more other pharmaceutical compositions.

10. The pharmaceutical composition as claimed in claim 9, wherein the composition is in the form selected from the group consisting of a tablet, capsule, powder, syrup, solution, aerosol and suspension.

11. Use of the compound of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI as claimed in any one of claims 1 – 6 or the pharmaceutical composition as claimed in claim 9 or 10, with other clinically relevant cytotoxic agents or non-cytotoxic agents in the manufacture of a medicament for treating and/or preventing diseases selected from cancer, HIV, Influenza, herpes virus, Hepatitis A, Hepatitis B, Hepatitis C, and Hepatitis D.

12. Use of a combination of the compound of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI as claimed in any of claims 1 – 6 or the pharmaceutical composition as claimed in claim 9 or 10, with other clinically relevant cytotoxic agents or non-cytotoxic agents in the manufacture of a medicament for treating cancer.

13. Use of a combination of the compound of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI as claimed in any of claims 1 – 6, or the pharmaceutical composition as claimed in claim 9 or 10, with other clinically relevant immune modulators agents in the manufacture of a medicament for treating cancer.